Aenova has announced a major expansion at its Bad Aibling facility, investing around €20 million to enhance production and packaging capabilities. The site, which serves as a competence centre for blister packaging and high-volume effervescent products, now boasts modern, high-speed manufacturing
Micreos Pharmaceuticals AG has entered into a strategic partnership with Northway Biotech, a Contract Development and Manufacturing Organization (CDMO), to advance the cGMP manufacturing of its biologic therapeutic, MEndoB. The investigational drug, a first-in-class dual-active domain targeted medicine, is set to enter clinical
Bionova Scientific, an Asahi Kasei company and boutique biologics contract development and manufacturing organisation (CDMO), has opened a new facility in Fremont, California. The 55,000 sq. ft. process development and pilot plant is designed to advance early-stage biologics assets to
Enzene has announced that its two facilities in Pune, India, have received European Union (EU) Good Manufacturing Practice (GMP) certification. The certification enables the company to supply commercial-scale microbial and mammalian drug substances, along with drug product fill/finish and packaging, to
AsymBio, the CDMO subsidiary of Asymchem Laboratories, has officially launched its new manufacturing base in Fengxian, Shanghai. The 120,000-square-metre facility will provide late-stage clinical and commercial manufacturing services for antibodies and bioconjugates. The first phase of the site, now operational,
Axplora, a global CDMO specialising in small-molecule APIs and ADCs, has expanded its payload manufacturing capabilities with the launch of a state-of-the-art GMP workshop at its Le Mans facility in France. The investment aims to meet the increasing demand for
Cerbios-Pharma has announced the opening of a new manufacturing expansion at its Lugano site, enhancing its capabilities for clinical and commercial production of Highly Potent Active Pharmaceutical Ingredients (HPAPIs). The facility will also support cytotoxic linker payloads for antibody-drug conjugates (ADCs).
ENCell has secured an 802 million won ($550,000) contract to provide contract development and manufacturing (CDMO) services for CELLeBRAIN, a Korean biotech developing gene-modified stem cell therapies for neurological diseases. The agreement, which runs until December 2025, tasks ENCell with producing CELLeBRAIN’s
Amneal Pharmaceuticals, Inc. and mAbxience have received FDA acceptance for the review of their Biologics License Application (BLA) for two proposed denosumab biosimilars, referencing Prolia and XGEVA. The FDA has assigned a target action date in the fourth quarter of 2025. Denosumab is
WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has introduced EffiX, a proprietary E. coli expression system engineered to enhance the production of recombinant proteins and plasmid DNA. The platform is designed to deliver high yields, exceptional
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
